Merck & Co has reached an agreement to buy Prometheus Biosciences in a $200-per-share cash transaction that values the San Diego-based biotech at $10.8 billion. The main object of the takeover is ...

Chinese consumers, once the engine of growth for multinational companies, are cutting back on all kinds of things. Designer ...

Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.

Merck's expansion into cardiovascular treatments and advancements in immunology and inflammation, partly through the Prometheus transaction, are seen as potential growth drivers by analysts.

Merck is kicking off a multi-part bond sale on Monday to help fund its US$10.8bn acquisition of Prometheus Biosciences that will give the pharmaceutical giant a foothold in therapies for immune ...

Merck issued a US$6bn jumbo bond on Monday to help fund its US$10.8bn acquisition of Prometheus Biosciences that will give the pharmaceutical giant a foothold in therapies for immune diseases as it ...

Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the ...

The startup’s management includes several from the executive team of Prometheus Biosciences, an immunology biotech bought by Merck last year.

like acquiring Acceleron and Prometheus, and cautious, like passing on Seagen due to valuation concerns. BofA Securities writes Merck stock's valuation was too low for an above-average growth profile.